Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
作者信息
Fung Monica, Schwartz Brian S, Doernberg Sarah B, Langelier Charles, Lo Mimi, Graff Larissa, Tan Marisela, Logan Aaron C, Chin-Hong Peter, Babik Jennifer M
机构信息
Division of Infectious Diseases, University of California San Francisco.
Department of Pharmacy, University of California San Francisco.
出版信息
Clin Infect Dis. 2018 Sep 14;67(7):1142-1143. doi: 10.1093/cid/ciy260.
Abstract
摘要
相似文献
1
Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?在使用艾沙康唑进行预防和治疗时出现的突破性侵袭性真菌感染：现实环境中发生了什么？
Clin Infect Dis. 2018 Sep 14;67(7):1142-1143. doi: 10.1093/cid/ciy260.
2
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.白血病患者接受伊曲康唑治疗后出现突破性真菌感染。
Clin Infect Dis. 2018 Oct 30;67(10):1610-1613. doi: 10.1093/cid/ciy406.
3
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.伊曲康唑治疗由一种以上真菌引起的侵袭性真菌病。
Mycoses. 2018 Jul;61(7):485-497. doi: 10.1111/myc.12777. Epub 2018 Apr 26.
4
Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.艾沙康唑用于治疗接受伊布替尼治疗的患者的侵袭性真菌病。
Leuk Lymphoma. 2019 Feb;60(2):527-530. doi: 10.1080/10428194.2018.1485913. Epub 2018 Jul 24.
5
[Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].[侵袭性真菌病的当前治疗选择及艾沙康唑的潜在治疗作用]
Rev Iberoam Micol. 2018 Oct-Dec;35(4):192-197. doi: 10.1016/j.riam.2018.07.003. Epub 2018 Nov 16.
6
Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.伊曲康唑预防和治疗侵袭性真菌感染：单中心经验。
Transpl Infect Dis. 2021 Apr;23(2):e13469. doi: 10.1111/tid.13469. Epub 2020 Nov 4.
7
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.在 3 期 SECURE 和 VITAL 试验中，用伊曲康唑或伏立康唑治疗侵袭性曲霉病患者的 MIC 值结果。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01634-18. Print 2019 Jan.
8
Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.伊曲康唑治疗涉及中枢神经系统的侵袭性真菌病患者。
Med Mycol. 2020 Jun 1;58(4):417-424. doi: 10.1093/mmy/myz103.
9
Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.硫酸异帕米星、伏立康唑和泊沙康唑治疗学术医疗中心侵袭性真菌感染的比较评价。
Ann Clin Microbiol Antimicrob. 2019 Mar 20;18(1):13. doi: 10.1186/s12941-019-0311-3.
10
[Invasive aspergillosis in solid organ transplantation].[实体器官移植中的侵袭性曲霉病]
Rev Iberoam Micol. 2018 Oct-Dec;35(4):206-209. doi: 10.1016/j.riam.2018.05.002. Epub 2018 Nov 20.
引用本文的文献
1
Incidence of Breakthrough Fungal Infections in Patients With Isavuconazole Prophylaxis: A Systematic Review and Meta-analysis.接受艾沙康唑预防治疗的患者中突破性真菌感染的发生率：一项系统评价和荟萃分析。
Open Forum Infect Dis. 2025 Mar 14;12(4):ofaf163. doi: 10.1093/ofid/ofaf163. eCollection 2025 Apr.
2
Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review.硫酸伊沙康唑在儿科肿瘤和干细胞移植人群中的使用和疗效特征：单机构回顾性研究。
J Pediatr Hematol Oncol. 2024 Mar 1;46(2):e143-e146. doi: 10.1097/MPH.0000000000002812. Epub 2024 Jan 17.
3
Subcutaneous zygomycosis in an immunocompetent patient caused by .免疫功能正常患者由……引起的皮下接合菌病
BMJ Case Rep. 2023 Jan 5;16(1):e253515. doi: 10.1136/bcr-2022-253515.
4
Mucormycosis co-infection in COVID-19 patients: An update.新型冠状病毒肺炎患者的毛霉菌病合并感染：最新进展
Open Life Sci. 2022 Aug 10;17(1):917-937. doi: 10.1515/biol-2022-0085. eCollection 2022.
5
Isavuconazole for COVID-19-Associated Invasive Mold Infections.艾沙康唑用于治疗新型冠状病毒肺炎相关侵袭性霉菌感染
J Fungi (Basel). 2022 Jun 28;8(7):674. doi: 10.3390/jof8070674.
6
Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread.COVID-19危机中的毛霉病：发病机制、诊断及对抗传播的新型治疗策略
Front Microbiol. 2022 Jan 4;12:794176. doi: 10.3389/fmicb.2021.794176. eCollection 2021.
7
Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole.艾沙康唑的治疗药物监测：与伏立康唑相比，血清浓度变异性及达标成功率
Antibiotics (Basel). 2021 Apr 23;10(5):487. doi: 10.3390/antibiotics10050487.
8
In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.毛霉目（毛霉亚门）临床相关成员的体外抗真菌药物耐药谱，尤其针对新型三唑类药物。
J Fungi (Basel). 2021 Apr 2;7(4):271. doi: 10.3390/jof7040271.
9
Isavuconazole-Animal Data and Clinical Data.艾沙康唑——动物数据与临床数据。
J Fungi (Basel). 2020 Oct 6;6(4):209. doi: 10.3390/jof6040209.
10
[Non-aspergillus molds infection after allogeneic stem cell transplantation: clinical analysis of 24 cases and outcomes].异基因造血干细胞移植后非曲霉菌感染：24例临床分析及转归
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):624-629. doi: 10.3760/cma.j.issn.0253-2727.2020.08.002.
本文引用的文献
1
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.白血病患者接受伊曲康唑治疗后出现突破性真菌感染。
Clin Infect Dis. 2018 Oct 30;67(10):1610-1613. doi: 10.1093/cid/ciy406.
2
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).血液系统恶性肿瘤患者侵袭性真菌感染的一级预防：德国血液学和医学肿瘤学会（DGHO）传染病工作组（AGIHO）2017年推荐更新版
Ann Hematol. 2018 Feb;97(2):197-207. doi: 10.1007/s00277-017-3196-2. Epub 2017 Dec 7.
3
Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.评估伊曲康唑和比较剂伏立康唑对 2635 株当代临床念珠菌和曲霉菌分离株的体外活性。
Clin Microbiol Infect. 2017 Nov;23(11):882-887. doi: 10.1016/j.cmi.2017.03.023. Epub 2017 Apr 1.
4
Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis.接受唑类预防治疗的患者中侵袭性霉菌感染的流行病学变化。
Clin Infect Dis. 2017 Jun 1;64(11):1619-1621. doi: 10.1093/cid/cix130.
5
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.伊曲康唑治疗毛霉病：一项单臂开放标签试验和病例对照分析。
Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9.
6
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.伊曲康唑与伏立康唑治疗曲霉菌和其他丝状真菌所致侵袭性霉菌病的初步治疗（SECURE）：一项 3 期随机对照非劣效性试验。
Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.
7
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.艾沙康唑用于中性粒细胞减少的急性髓系白血病患者抗真菌预防的安全性和药代动力学：一项2期剂量递增研究的结果
Antimicrob Agents Chemother. 2015 Apr;59(4):2078-85. doi: 10.1128/AAC.04569-14. Epub 2015 Jan 26.
8
Antifungal prophylaxis in lung transplantation--a world-wide survey.肺移植中的抗真菌预防 - 一项全球性调查。
Am J Transplant. 2011 Feb;11(2):361-6. doi: 10.1111/j.1600-6143.2010.03375.x. Epub 2011 Jan 10.
9
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.侵袭性真菌病临床试验中治疗反应和研究结果的定义：真菌病研究组和欧洲癌症研究与治疗组织共识标准
Clin Infect Dis. 2008 Sep 1;47(5):674-83. doi: 10.1086/590566.
Zotero 插件